ArticleGastro hep advances2026
Health Disparities in Hepatitis D Virus Management: A Case Series on Improving Patient Access to Bulevirtide Therapy.
Article in Gastro hep advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Migrants and those from marginalized backgrounds with hepatitis D virus (HDV) often face social or health challenges that can impair access to care and adherence to treatment. This case series seeks to highlight that such challenges can be overcome and should not be seen as insurmountable barriers to the initiation of bulevirtide for HDV. Methods: Four consenting, anonymized patients were retrospectively identified from UK centers by a multidisciplinary authorship group. Results: Identified patients represented 4 different social circumstances that may impair treatment adherence: patient 1 had a history of mental health issues and was recently evicted; patient 2 was living in a homeless shelter, without access to a fridge or to a safe, confidential space for bulevirtide administration and disposal; patient 3 had a history of illicit drug use and previously failed to engage with care; and patient 4 failed to maintain injections following an unplanned trip to Africa. Each patient achieved positive results with bulevirtide therapy-demonstrating a reduced viral load and improvements in key measures of hepatic function-with adjustments made to their care to account for their unique needs. This included initiating therapy at a time that accommodated their personal circumstances, pausing treatment as needed, and working with third-party services to provide practical support that could address medication storage and logistical challenges. Conclusion: By shifting the perception that social circumstances are barriers to adherence, healthcare providers can promote a more inclusive approach to initiating, maintaining, and, where necessary, restarting bulevirtide therapy, ultimately improving health outcomes for patients with HDV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.